Makrolidlere ve Linkozamidlere Direnç Mekanizmaları

Vázquez-Laslop N, Mankin AS. How Macrolide Antibiotics Work. Trends in biochemical sciences. 2018;43(9): 668-684. doi: 10.1016/j.tibs.2018.06.011

McGuire JM, Bunch RL, Anderson RC, et al. Ilotycin, a new antibiotic. Schweizerische medizinische Wochenschrift. 1952;82(41): 1064-1065.

Cattoir V, Lerlercq R. Resistance to Macrolides, Lincosamides, and Streptogramines. In: Mayers DL, Lerner SA, Ouellette M, (eds). Antimicrobial drug resistance, Volume 1. 2nd ed. Springer; 2009. p. 269-279

Dinos GP. The macrolide antibiotic renaissance. British journal of pharmacology. 2017;174(18): 2967-2983. doi: 10.1111/bph.13936

Feßler AT, Wang Y, Wu C, et al. Mobile lincosamide resistance genes in staphylococci. Plasmid. 2018;99: 22-31. doi: 10.1016/j.plasmid.2018.06.002

Weisblum B. Erythromycin resistance by ribosome modification. Antimicrobial agents and chemotherapy. 1995;39(3): 577-585. doi: 10.1128/aac.39.3.577

Katz L, Brown D, Boris K, et al. Expression of the macrolide-lincosamide-streptogramin-B-resistance methylase gene, ermE, from Streptomyces erythraeus in Escherichia coli results in N6-monomethylation and N6,N6-dimethylation of ribosomal RNA. Gene. 1987;55(2-3): 319-325. doi: 10.1016/0378-1119(87)90291-5

Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell. 2007;128(6): 1037-1050.

Webb V, Davies J. Antibiotic preparations contain DNA: a source of drug resistance genes? Antimicrobial agents and chemotherapy. 1993;37(11): 2379-2384. doi: 10.1128/aac.37.11.2379

Webb V, Davies J. Accidental release of antibiotic-resistance genes. Trends in biotechnology. 1994;12(3): 74-75. doi: 10.1016/0167-7799(94)90108-2

Ramu H, Mankin A, Vazquez‐Laslop N. Programmed drug‐dependent ribosome stalling. Molecular microbiology. 2009;71(4): 811-824. doi: 10.1111/j.1365-2958.2008.06576.x

Poehlsgaard J, Douthwaite S. Macrolide antibiotic interaction and resistance on the bacterial ribosome. Current Opinion in Investigational Drugs. 2003;4(2): 140-148.

Miklasińska-Majdanik M. Mechanisms of Resistance to Macrolide Antibiotics among Staphylococcus aureus. Antibiotics (Basel, Switzerland). 2021;10(11). doi: 10.3390/antibiotics10111406

The European Committee on Antimicrobial Susceptibility Testing ( EUCAST). Clinical breakpoints - breakpoints and guidance. Available from:https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.xlsx. (Accessed 15th December 2022).

Clarebout G, Nativelle E, Leclercq R. Unusual inducible cross resistance to macrolides, lincosamides, and streptogramins B by methylase production in clinical isolates of Staphylococcus aureus. Microbial drug resistance (Larchmont, NY). 2001;7(4): 317-322. doi: 10.1089/10766290152773329

Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Molecular Microbiology. 2007;64(6): 1506-1514. doi: 10.1111/j.1365-2958.2007.05744.x

Tait-Kamradt A, Davies T, Cronan M, et al. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrobial agents and chemotherapy. 2000;44(8): 2118-2125. doi: 10.1128/aac.44.8.2118-2125.2000

Farrell DJ, Douthwaite S, Morrissey I, et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrobial agents and chemotherapy. 2003;47(6): 1777-1783. doi: 10.1128/aac.47.6.1777-1783.2003

Spížek J, Řezanka T. Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications. Biochemical pharmacology. 2017;133: 20-28. doi: 10.1016/j.bcp.2016.12.001

Canu A, Malbruny B, Coquemont M, et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrobial agents and chemotherapy. 2002;46(1): 125-131. doi: 10.1128/AAC.46.1.125-131.2

Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2002;34(4): 482-492. doi: 10.1086/324626

Sutcliffe JA, Leclercq R. Mechanisms of resistance to macrolides, lincosamides, and ketolides. In: Schonfeld W, Kirst HA (eds). Macrolide antibiotics. Springer; 2003. p. 281-317.

Shakya T, Wright GD. Nucleotide selectivity of antibiotic kinases. Antimicrobial agents and chemotherapy. 2010;54(5): 1909-1913. doi: 10.1128/aac.01570-09

Chesneau O, Tsvetkova K, Courvalin P. Resistance phenotypes conferred by macrolide phosphotransferases. FEMS microbiology letters. 2007;269(2): 317-322. doi: 10.1111/j.1574-6968.2007.00643.x

Phuc Nguyen MC, Woerther PL, Bouvet M, et al. Escherichia coli as reservoir for macrolide resistance genes. Emerging infectious diseases. 2009;15(10): 1648-1650. doi: 10.3201/eid1510.090696

Nonaka L, Maruyama F, Suzuki S, et al. Novel macrolide-resistance genes, mef(C) and mph(G), carried by plasmids from Vibrio and Photobacterium isolated from sediment and seawater of a coastal aquaculture site. Letters in applied microbiology. 2015;61(1): 1-6. doi: 10.1111/lam.12414

Barthélémy P, Autissier D, Gerbaud G, et al. Enzymic hydrolysis of erythromycin by a strain of Escherichia coli. A new mechanism of resistance. The Journal of antibiotics. 1984;37(12): 1692-1696. doi: 10.7164/antibiotics.37.1692

Wondrack L, Massa M, Yang BV, et al. Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. Antimicrobial agents and chemotherapy. 1996;40(4): 992-998. doi: 10.1128/aac.40.4.992

Schmitz FJ, Sadurski R, Kray A, et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. The Journal of antimicrobial chemotherapy. 2000;45(6): 891-894. doi: 10.1093/jac/45.6.891

Kim YH, Cha CJ, Cerniglia CE. Purification and characterization of an erythromycin esterase from an erythromycin-resistant Pseudomonas sp. FEMS microbiology letters. 2002;210(2): 239-244. doi: 10.1111/j.1574-6968.2002.tb11187.x

Bozdogan B, Berrezouga L, Kuo MS, et al. A new resistance gene, linB, conferring resistance to lincosamides by nucleotidylation in Enterococcus faecium HM1025. Antimicrobial agents and chemotherapy. 1999;43(4): 925-929. doi: 10.1128/aac.43.4.925

Heir E, Lindstedt BA, Leegaard TM, et al. Prevalence and characterization of integrons in blood culture Enterobacteriaceae and gastrointestinal Escherichia coli in Norway and reporting of a novel class 1 integron-located lincosamide resistance gene. Annals of clinical microbiology and antimicrobials. 2004;3: 12. doi: 10.1186/1476-0711-3-12

Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs. 2004;64(2): 159-204. doi: 10.2165/00003495-200464020-00004

Sharkey LK, Edwards TA, O'Neill AJ. ABC-F Proteins Mediate Antibiotic Resistance through Ribosomal Protection. mBio. 2016;7(2): e01975. doi: 10.1128/mBio.01975-15

Wilson DN. The ABC of Ribosome-Related Antibiotic Resistance. mBio. 2016;7(3). doi: 10.1128/mBio.00598-16

Ross JI, Eady EA, Cove JH, et al. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Molecular Microbiology. 1990;4(7): 1207-1214. doi: 10.1111/j.1365-2958.1990.tb00696.x

Ahirrao P, Tambat R, Chandal N, et al. MsrA Efflux Pump Inhibitory Activity of Piper cubeba L.f. and its Phytoconstituents against Staphylococcus aureus RN4220. Chemistry & biodiversity. 2020;17(8): e2000144. doi: 10.1002/cbdv.202000144

Ojo KK, Striplin MJ, Ulep CC, et al. Staphylococcus efflux msr(A) gene characterized in Streptococcus, Enterococcus, Corynebacterium, and Pseudomonas isolates. Antimicrobial agents and chemotherapy. 2006;50(3): 1089-1091. doi: 10.1128/aac.50.3.1089-1091.2006

Law CJ, Maloney PC, Wang DN. Ins and outs of major facilitator superfamily antiporters. Annual review of microbiology. 2008;62: 289-305. doi: 10.1146/annurev.micro.61.080706.093329

Ojo KK, Ulep C, Van Kirk N, et al. The mef(A) gene predominates among seven macrolide resistance genes identified in gram-negative strains representing 13 genera, isolated from healthy Portuguese children. Antimicrobial agents and chemotherapy. 2004;48(9): 3451-3456. doi: 10.1128/aac.48.9.3451-3456.2004

Clancy J, Petitpas J, Dib-Hajj F, et al. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Molecular Microbiology. 1996;22(5): 867-879. doi: 10.1046/j.1365-2958.1996.01521.x

Nunez-Samudio V, Chesneau O. Functional interplay between the ATP binding cassette Msr(D) protein and the membrane facilitator superfamily Mef(E) transporter for macrolide resistance in Escherichia coli. Research in microbiology. 2013;164(3): 226-235. doi: 10.1016/j.resmic.2012.12.003

Fyfe C, Grossman TH, Kerstein K, et al. Resistance to Macrolide Antibiotics in Public Health Pathogens. Cold Spring Harbor perspectives in medicine. 2016;6(10): a025395. doi: 10.1101/cshperspect.a025395

Hot C, Berthet N, Chesneau O. Characterization of sal(A), a novel gene responsible for lincosamide and streptogramin A resistance in Staphylococcus sciuri. Antimicrobial agents and chemotherapy. 2014;58(6): 3335-3341. doi: 10.1128/aac.02797-13